Your browser is no longer supported. Please, upgrade your browser.
Settings
ABEO [NASD]
Abeona Therapeutics Inc.
Index- P/E- EPS (ttm)-0.57 Insider Own2.50% Shs Outstand97.99M Perf Week-4.82%
Market Cap77.04M Forward P/E- EPS next Y-0.56 Insider Trans-5.70% Shs Float86.01M Perf Month-14.12%
Income-54.10M PEG- EPS next Q-0.10 Inst Own25.90% Short Float3.09% Perf Quarter-44.27%
Sales3.00M P/S25.68 EPS this Y40.00% Inst Trans-7.65% Short Ratio3.79 Perf Half Y-55.76%
Book/sh0.81 P/B0.90 EPS next Y6.30% ROA-39.90% Target Price5.00 Perf Year-48.23%
Cash/sh0.63 P/C1.15 EPS next 5Y- ROE-60.00% 52W Range0.73 - 3.79 Perf YTD-53.50%
Dividend- P/FCF- EPS past 5Y-11.50% ROI-78.10% 52W High-80.74% Beta1.39
Dividend %- Quick Ratio2.60 Sales past 5Y57.30% Gross Margin- 52W Low0.00% ATR0.06
Employees76 Current Ratio2.60 Sales Q/Q- Oper. Margin- RSI (14)30.70 Volatility7.83% 7.96%
OptionableYes Debt/Eq0.00 EPS Q/Q6.90% Profit Margin- Rel Volume1.03 Prev Close0.76
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume701.27K Price0.73
Recom1.70 SMA20-15.51% SMA50-23.55% SMA200-50.63% Volume723,455 Change-3.57%
Nov-11-20Upgrade Cantor Fitzgerald Neutral → Overweight $4
Sep-18-20Initiated B. Riley FBR Buy $5
Feb-10-20Initiated SVB Leerink Outperform $6
Dec-10-19Resumed Cantor Fitzgerald Neutral $2 → $4
Aug-15-19Downgrade Maxim Group Buy → Hold
Aug-12-19Downgrade Cantor Fitzgerald Overweight → Neutral $29 → $2
Jul-26-19Downgrade Mizuho Buy → Neutral $17 → $4
Jun-27-19Initiated Mizuho Buy
Oct-12-18Initiated Mizuho Buy $17
Jun-05-18Initiated Seaport Global Securities Buy $29
Nov-08-17Initiated SunTrust Buy $26
Oct-16-17Reiterated H.C. Wainwright Buy $20 → $30
Oct-11-17Reiterated Cantor Fitzgerald Overweight $21 → $34
Oct-10-17Initiated Citigroup Buy $32
Oct-05-17Reiterated Maxim Group Buy $17 → $35
Sep-15-17Initiated RBC Capital Mkts Outperform $23
Jul-18-17Reiterated Maxim Group Buy $14 → $17
Jun-22-17Resumed Jefferies Buy $22
Jan-06-17Initiated Jefferies Buy
Sep-29-16Reiterated Maxim Group Buy $8 → $14
Nov-19-21 10:00AM  
Nov-18-21 07:30AM  
Nov-17-21 07:30AM  
Nov-16-21 07:30AM  
Nov-15-21 07:45AM  
07:12AM  
Oct-21-21 07:30AM  
06:21AM  
Oct-13-21 07:30AM  
Oct-12-21 07:30AM  
Sep-21-21 04:01PM  
Sep-07-21 07:30AM  
Aug-10-21 07:30AM  
Jul-28-21 04:01PM  
07:30AM  
Jul-26-21 07:30AM  
06:12AM  
Jul-23-21 07:30AM  
Jul-07-21 12:02PM  
07:30AM  
Jun-14-21 10:00AM  
Jun-02-21 07:30AM  
May-26-21 07:30AM  
May-25-21 07:30AM  
06:45AM  
May-18-21 07:30AM  
May-11-21 06:06AM  
Apr-20-21 07:30AM  
Apr-19-21 07:30AM  
Mar-25-21 07:30AM  
Mar-24-21 05:15PM  
04:01PM  
Mar-23-21 12:41PM  
Mar-22-21 07:30AM  
Mar-11-21 11:22PM  
Feb-25-21 11:33AM  
Feb-22-21 07:30AM  
Feb-12-21 11:36AM  
Feb-02-21 07:30AM  
Jan-25-21 07:30AM  
Jan-12-21 08:50AM  
Dec-21-20 12:20PM  
Dec-14-20 09:44PM  
Dec-01-20 10:06AM  
09:09AM  
Nov-27-20 08:25AM  
Nov-24-20 03:10PM  
03:08PM  
03:07PM  
Nov-18-20 11:24AM  
Nov-17-20 01:16PM  
Nov-12-20 05:21AM  
Nov-09-20 05:55PM  
04:05PM  
Oct-27-20 06:30AM  
Oct-14-20 10:58PM  
Oct-06-20 04:01PM  
Sep-28-20 09:27AM  
Sep-18-20 11:08AM  
09:31AM  
Sep-08-20 04:05PM  
Sep-01-20 06:29AM  
Aug-17-20 07:00AM  
Aug-10-20 04:01PM  
Aug-04-20 11:36AM  
Jul-10-20 07:30AM  
Jul-09-20 09:10AM  
07:30AM  
Jul-08-20 07:30AM  
Jul-03-20 07:48AM  
Jun-23-20 11:59AM  
Jun-18-20 07:30AM  
Jun-17-20 07:30AM  
Jun-08-20 09:11AM  
May-28-20 11:30AM  
08:30AM  
May-08-20 12:58PM  
May-07-20 01:59PM  
May-06-20 04:14PM  
Apr-29-20 11:08AM  
Apr-21-20 04:04PM  
08:00AM  
Apr-20-20 08:43AM  
06:06AM  
Apr-17-20 07:00AM  
Apr-06-20 09:16AM  
Apr-05-20 04:12AM  
Mar-27-20 06:19PM  
Mar-23-20 12:00PM  
Mar-17-20 07:30AM  
Mar-16-20 04:20PM  
Feb-26-20 08:00AM  
Feb-21-20 08:45AM  
Feb-12-20 02:15PM  
Jan-21-20 08:00AM  
Jan-15-20 09:33AM  
Jan-13-20 09:00AM  
Jan-02-20 12:12PM  
11:55AM  
10:28AM  
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead programs include EB-101, an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa; ABO-102, an adeno-associated virus-based gene therapy for Sanfilippo syndrome type A; and ABO-101, an AAV-based gene therapy for Sanfilippo syndrome type B. The company also develops ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-5OX for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was founded in 1974 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
O'Malley Brendan M.SVP, General CounselNov 05Sale0.898,8807,894213,630Nov 05 07:00 PM
O'Malley Brendan M.SVP, General CounselOct 11Sale0.9025,73423,271222,510Oct 13 07:08 PM
O'Malley Brendan M.SVP, General CounselOct 08Sale1.0522,76323,915248,244Oct 08 08:31 PM
CARR EDWARDChief Financial OfficerOct 08Sale1.0529,12230,596400,169Oct 08 08:29 PM
Wider ToddDirectorOct 07Sale0.9725,00024,1500Oct 08 08:33 PM
O'Malley Brendan M.SVP, General CounselOct 05Sale1.052,4472,569271,007Oct 08 08:31 PM
Amoroso MichaelChief Executive OfficerSep 30Sale1.0945,40949,382604,637Oct 04 04:06 PM
CARR EDWARDChief Accounting OfficerApr 05Sale1.8035,00062,846191,291Apr 05 06:31 PM
CARR EDWARDChief Accounting OfficerApr 01Sale1.8520,44537,866226,291Apr 05 06:31 PM
Amoroso MichaelChief Executive OfficerMar 31Sale1.8745,40984,919650,046Apr 02 07:12 PM
SCO CAPITAL PARTNERS LLCDirectorMar 18Sale2.2380,000178,62411,159,292Mar 19 04:05 PM
Mann Paul ElliotDirectorFeb 19Option Exercise1.2845,56658,32445,566Feb 23 04:14 PM
Mann Paul ElliotDirectorFeb 19Sale2.3845,566108,5020Feb 23 04:14 PM
Wider ToddDirectorFeb 19Sale2.39251,625601,05725,000Feb 23 04:05 PM
Wider ToddDirectorFeb 18Option Exercise1.281,3451,722277,970Feb 19 04:05 PM
Wider ToddDirectorFeb 18Sale2.431,3453,273276,625Feb 19 04:05 PM
Wider ToddDirectorFeb 17Option Exercise1.28320,000409,600596,625Feb 19 04:05 PM
Wider ToddDirectorFeb 17Sale2.34320,000749,792276,625Feb 19 04:05 PM
Mann Paul ElliotDirectorFeb 17Sale2.34132,664310,1680Feb 19 04:05 PM
SCO CAPITAL PARTNERS LLCDirectorFeb 16Sale2.97120,000356,80811,239,292Feb 18 04:05 PM
SCO CAPITAL PARTNERS LLCDirectorFeb 08Sale3.01240,000722,83211,359,292Feb 10 07:42 PM
SCO CAPITAL PARTNERS LLCDirectorJan 19Sale2.08207,117431,21811,599,292Jan 19 06:48 PM
SCO CAPITAL PARTNERS LLCDirectorJan 15Sale2.0281,283164,08611,806,409Jan 19 06:48 PM
SCO CAPITAL PARTNERS LLCDirectorJan 14Sale2.0031,60063,21311,887,692Jan 19 06:48 PM
Wider ToddDirectorJan 04Sale1.5433,87652,064276,625Jan 05 07:09 PM
Mann Paul ElliotDirectorJan 04Sale1.5430,48846,891132,664Jan 05 07:07 PM
Mann Paul ElliotDirectorDec 18Sale1.5917,07927,099772,907Dec 21 06:16 PM
Wider ToddDirectorDec 02Sale1.4933,87650,546920,256Dec 02 04:26 PM
Mann Paul ElliotDirectorDec 02Sale1.4930,48845,369789,986Dec 02 04:25 PM